Oncogene Cancer Research shared on LinkedIn:
“At 38, Mayya had the newborn, the toddler, the big career and the happy marriage. Life was moving at full speed, exactly as planned.
Then came stage 4 ALK+ lung cancer.
Her first treatment brought an extraordinary response. Eight months later, the cancer had progressed throughout her body – and no one could explain why.
Mayya built her team. Asked harder questions. Has continued to keep pushing for more.
Read Mayya’s story full in our website to learn more about her journey and why patients need to be informed so we can best participate in our treatment decisions.
Thanks to our sponsors Amgen, Nuvalent, Inc., Takeda Oncology and Thermo Fisher Scientific, who have no editorial control over the content.”
You can also read 2026 LCRF Award on Advancing Breakthroughs in ALK-Positive Lung Cancer on OncoDaily.
